You just read:

Amgen Submits Supplemental Biologics License Application For BLINCYTO® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

News provided by

Amgen

Feb 14, 2017, 09:00 ET